window.pageData = {"stock":{"_id":3000000025174,"stockCode":"025174","masterFundShortName":"长城港股医疗保健精选混合发起（QDII）","fundSecondLevel":"QDII","stockType":"fund","areaCode":"cn","market":"a","tickerId":25174,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"长城港股医疗保健精选混合发起（QDII）A","name":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）","pinyin":"ccggylbjjxhhxfqszqtzjj(qdii)","fundCollectionId":4000050150000,"setUpAssetScale":40180690.84,"setUpDate":"2025-08-19T16:00:00.000Z","setUpShares":40180690.84,"inceptionDate":"2025-08-21T16:00:00.000Z","followedNum":1,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50150000","tickerId":50150000,"name":"长城基金管理有限公司"},"managers":[{"name":"曲少杰","stockType":"fund_manager","stockCode":"8801613552","exchange":"fm","tickerId":171910191320},{"name":"梁福睿","stockType":"fund_manager","stockCode":"j101019899","exchange":"fm","tickerId":120618242860}],"hotMetrics":{"fpr":{"stockId":3000000025174,"type":"fpr","f_p_r_m1_ssc":587,"f_p_r_m1_ssrp":0.9948805460750854,"f_cagr_p_r_fs_ssc":589,"f_cagr_p_r_fs_ssrp":0.9948979591836735,"f_p_r_m3_ssc":578,"f_p_r_m3_ssrp":0.6811091854419411,"f_p_r_fys_ssc":573,"f_p_r_fys_ssrp":0.548951048951049,"f_p_r_m6_ssc":570,"f_p_r_m6_ssrp":0.7293497363796133},"fp":{"stockId":3000000025174,"type":"fp","last_data_date":"2026-05-17T16:00:00.000Z","f_p_r_m1":-0.17465466722478062,"f_cagr_p_r_fs":-0.21130000000000004,"f_p_r_m3":-0.05916736251938515,"f_p_r_fys":-0.0032857323391890514,"f_p_r_m6":-0.07808299240210459},"f_nlacan":{"stockId":3000000025174,"type":"f_nlacan","f_nv_d":"2026-05-17T16:00:00.000Z","f_nv":0.7887,"f_nv_cr":-0.02448979591836742},"f_as":{"stockId":3000000025174,"type":"f_as","f_tas":23215123.4805,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000025175,"name":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）","fundSecondLevel":"QDII","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"025175","tickerId":25175,"shortName":"长城港股医疗保健精选混合发起（QDII）C","currency":"CNY","__csrcFundId":15578,"exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2025-09-19T18:02:03.000Z","inceptionDate":"2025-08-21T16:00:00.000Z","pinyin":"ccggylbjjxhhxfqszqtzjj(qdii)","fundCollectionId":4000050150000}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000002142,"holdings":500244,"marketCap":5786144,"netValueRatio":0.0723,"quarterlyChange":0.07730263157894623,"stock":{"stockType":"company","exchange":"hk","stockCode":"02142","tickerId":2142,"name":"和铂医药-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000002696,"holdings":92020,"marketCap":5667121,"netValueRatio":0.0708,"quarterlyChange":0.22261174408413775,"stock":{"stockCode":"02696","exchange":"hk","stockType":"company","tickerId":2696,"name":"复宏汉霖"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000001801,"holdings":72000,"marketCap":5397296,"netValueRatio":0.0674,"quarterlyChange":0.11344262295081897,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000006990,"holdings":12400,"marketCap":5036346,"netValueRatio":0.0629,"quarterlyChange":0.17287098419173907,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000009926,"holdings":43000,"marketCap":4943283,"netValueRatio":0.0617,"quarterlyChange":0.1522123893805305,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000009606,"holdings":17300,"marketCap":4506135,"netValueRatio":0.0563,"quarterlyChange":-0.010731052984573997,"stock":{"exchange":"hk","stockType":"company","stockCode":"09606","tickerId":9606,"name":"映恩生物-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000002256,"holdings":393842,"marketCap":4204210,"netValueRatio":0.0525,"quarterlyChange":-0.07071483474250573,"stock":{"exchange":"hk","stockType":"company","stockCode":"02256","tickerId":2256,"name":"和誉-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000009887,"holdings":61608,"marketCap":4025361,"netValueRatio":0.0503,"quarterlyChange":0.45098039215686203,"stock":{"exchange":"hk","stockType":"company","stockCode":"09887","tickerId":9887,"name":"维立志博-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025174,"stockId":1000000000001530,"holdings":184500,"marketCap":3688152,"netValueRatio":0.0461,"quarterlyChange":-0.06368899917286963,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}}]},"list":[{"_id":"69e8ecb11398d79843fea0e8","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000025174,"sao":"2026年一季度，创新药板块整体呈现先抑后扬、月末爆发的走势，核心标的经历了深度调整后的强势反弹，而a股小市值属性的创新药及产业链表现也较为突出。因为中国创新药在免疫疗法、ADC、TCE等技术研发领域开始引领全球，诸多公司BD给海外药企的管线在26年内加速推进，同时创新药龙头公司有望在27年批量式盈利或大幅减亏，本季度增配了具有全球技术平台优势、核心管线具有海外进展和巨大报表拐点的创新药个股，因海外宏观事件有可能带来流动性枯竭，减配了部分交易量较小的个股仓位，此外AACR、ASCO等国际会议有望继续验证和分辨管线疗效及技术平台的优劣。　　本报告期长城港股医疗保健精选混合发起（QDII）A基金份额净值增长率为8.04%，同期业绩比较基准收益率为-1.00%；长城港股医疗保健精选混合发起（QDII）C基金份额净值增长率为7.88%，同期业绩比较基准收益率为-1.00%。","lastUpdated":"2026-04-22T15:43:45.162Z","fund":{"_id":3000000025174,"__csrcFundId":15578,"stockCode":"025174","masterFundShortName":"长城港股医疗保健精选混合发起（QDII）","fundSecondLevel":"QDII","stockType":"fund","areaCode":"cn","market":"a","tickerId":25174,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"长城港股医疗保健精选混合发起（QDII）(025174)","lastUpdated":"2026-05-01T04:35:48.698Z","name":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）","pinyin":"ccggylbjjxhhxfqszqtzjj(qdii)","fundCollectionId":4000050150000,"setUpAssetScale":40180690.84,"setUpDate":"2025-08-19T16:00:00.000Z","setUpShares":40180690.84,"inceptionDate":"2025-08-21T16:00:00.000Z","followedNum":1,"managers":[{"stockCode":"8801613552","stockType":"fund_manager","exchange":"fm","tickerId":171910191320,"name":"曲少杰"},{"stockCode":"j101019899","stockType":"fund_manager","exchange":"fm","tickerId":120618242860,"name":"梁福睿"}]},"announcement":{"linkText":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1479822","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed40c7fea5b3eb054412d","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-21T16:00:00.000Z","stockId":3000000025174,"sao":"本报告期长城港股医疗保健精选混合发起（QDII）A基金份额净值增长率为-22.28%，同期业绩比较基准收益率为-16.59%；长城港股医疗保健精选混合发起（QDII）C基金份额净值增长率为-22.40%，同期业绩比较基准收益率为-16.59%。　　2025 年第四季度 A 股呈现 “冲高 - 回落 - 翘尾” 的震荡上行格局，主题行情维持主导格局，H 股则是震荡整理、阶段性明显跑输 A 股，两者均受政策、流动性与盈利预期驱动，但港股额外承压于海外流动性与资金偏好差异，从而导致港股创新药季度内较长时间缺乏流动性支撑，调整时间和调整幅度大幅超过市场和个人预期，当前时间点诸多创新药个股因未入通从而有流动性折价，在基本面兑现及港股整体流动性回归后会有戴维斯双击可能。持仓个股在原有选股角度的基础上，因四季度核心创新药白马逐渐调整，择机增加了港股通创新药仓位，策略上调整整体持仓形成“已BD”和“未BD”两条配置线，“已BD”类型个股以MNC内部管线重视度及全球核心临床推进节奏为抓手，“未BD”个股更多基于核心管线全球竞争力和稀缺性的逻辑，并进一步在个股远期空间、成药确定性、出海确定性之间调整了平衡，同时考虑港股IPO井喷，后续也会新增持有基本面强、管理层专业且踏实的新股。","lastUpdated":"2026-03-09T14:07:08.015Z","fund":{"_id":3000000025174,"__csrcFundId":15578,"stockCode":"025174","masterFundShortName":"长城港股医疗保健精选混合发起（QDII）","fundSecondLevel":"QDII","stockType":"fund","areaCode":"cn","market":"a","tickerId":25174,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"长城港股医疗保健精选混合发起（QDII）(025174)","lastUpdated":"2026-05-01T04:35:48.698Z","name":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）","pinyin":"ccggylbjjxhhxfqszqtzjj(qdii)","fundCollectionId":4000050150000,"setUpAssetScale":40180690.84,"setUpDate":"2025-08-19T16:00:00.000Z","setUpShares":40180690.84,"inceptionDate":"2025-08-21T16:00:00.000Z","followedNum":1,"managers":[{"stockCode":"8801613552","stockType":"fund_manager","exchange":"fm","tickerId":171910191320,"name":"曲少杰"},{"stockCode":"j101019899","stockType":"fund_manager","exchange":"fm","tickerId":120618242860,"name":"梁福睿"}]},"announcement":{"linkText":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1459343","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed40c7fea5b3eb054412c","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000025174,"sao":"本报告期长城港股医疗保健精选混合发起（QDII）A基金份额净值增长率为1.57%，同期业绩比较基准收益率为2.15%；长城港股医疗保健精选混合发起（QDII）C基金份额净值增长率为1.51%，同期业绩比较基准收益率为2.15%。　　三季度A/H市场呈现多个板块齐涨的现象，A股成交量在本季度后段逐渐提升，资本市场的交投情绪较为活跃；而H股9月在通过科技股驱动背景下港股已重拾升势，且南下资金体量创历史新高。在科技类板块涨幅较好的背景下，创新药作为二季度具有科技属性的优势资产反而逐渐进入调整阶段，一方面主因上半年涨幅较大较快，另一方面以TMT为主的科技资产带来了资金层面的负面影响，增量资金离场导致三季度内A股创新药回调幅度远大于H股，当前时间点诸多创新药个股已经极具性价比。三季度内持仓个股更多集中在非港股通公司，主因此类公司估值更为合理，临床布局更为前瞻，同时亦因流通盘较小而波动更大，所以持仓更需要围绕临床数据读出节奏和管线全球竞争力及管线海外授权三个角度展开，并重点布局了未来短期有望纳入港股通的优质标的，而海外授权预期逐渐回归平稳是持仓个股股价回调的主要因素，后续持仓个股在原有选股角度的基础上，会加大核心管线稀缺性的选股权重，并会择机加配与当前持仓具有适应症互补的个股，力争在个股远期空间、成药确定性、出海确定性之间寻找更好的平衡。","lastUpdated":"2026-03-09T14:07:08.012Z","fund":{"_id":3000000025174,"__csrcFundId":15578,"stockCode":"025174","masterFundShortName":"长城港股医疗保健精选混合发起（QDII）","fundSecondLevel":"QDII","stockType":"fund","areaCode":"cn","market":"a","tickerId":25174,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"长城港股医疗保健精选混合发起（QDII）(025174)","lastUpdated":"2026-05-01T04:35:48.698Z","name":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）","pinyin":"ccggylbjjxhhxfqszqtzjj(qdii)","fundCollectionId":4000050150000,"setUpAssetScale":40180690.84,"setUpDate":"2025-08-19T16:00:00.000Z","setUpShares":40180690.84,"inceptionDate":"2025-08-21T16:00:00.000Z","followedNum":1,"managers":[{"stockCode":"8801613552","stockType":"fund_manager","exchange":"fm","tickerId":171910191320,"name":"曲少杰"},{"stockCode":"j101019899","stockType":"fund_manager","exchange":"fm","tickerId":120618242860,"name":"梁福睿"}]},"announcement":{"linkText":"长城港股医疗保健精选混合型发起式证券投资基金（QDII）2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1381130","linkType":"PDF","source":"csrc_pdf"}}]}